Keishinkai Medical Corporation (Shinjuku-ku, Tokyo) officially launched its website on June 16, 2026 (Tue) concerning Treg therapy ("TALS Therapy") for ALS (Amyotrophic Lateral Sclerosis).
This website is an informational site for ALS patients and their families, introducing the new treatment method "TALS Therapy" focusing on regulatory T cells (Treg) with the latest medical evidence, allowing them to consider it as a new option with peace of mind.
Official Website URL
https://tals-treatment.com/
Website Top Page
Purpose and Background of Official Website Launch
ALS is a progressive intractable disease in which motor neurons are affected, leading to a decline in overall muscle strength. Recent medical research has revealed that "neuroinflammation" in the brain and spinal cord is deeply involved in its progression.
Our corporation has newly initiated "TALS Therapy," which focuses on regulatory T cells (Treg), acting as a "brake" for inflammation in the immune system.
Because it is a new treatment method, this site clearly explains the medical evidence with videos to ensure patients and their families can consider it with confidence. Furthermore, we have gathered information that patients would want to know from their perspective, including the treatment flow, costs, and optional outpatient/stay support.
Two Consultation Services to Address Pre-Treatment Concerns
To support patients and families in making informed decisions, we have prepared two services available before proceeding with treatment:
1. Online Consultation with Staff (Free)
Available from the stage of "I just want to hear about it" before wishing for specific treatment. Specialized staff within our corporation will provide information on the treatment flow, costs, etc., and support in organizing questions and concerns regarding consultation.
2. Online Medical Examination by a Neurologist (Self-pay/Private Practice)
For those considering specific treatment, a neurologist affiliated with our partner clinic will provide online consultations. Through a detailed medical interview, we will offer consultations from a medical perspective on the possibility of treatment adaptation based on current symptoms and progress.
Through these two services, we are creating an environment where treatment can be considered with peace of mind.
Main Contents
- Explanation of the relationship between ALS and neuroinflammation
- Mechanism and characteristics of TALS Therapy
- Information on free consultations with staff and online medical examinations by doctors (self-pay/private practice)
- Information on treatment flow and costs
- Information on medical support such as outpatient visits, accommodation, and medical visas for domestic and international patients
- Introduction of the medical team and cell processing facility
Provision System
This treatment is provided under advanced medical safety management, leveraging the expertise of facilities operated by Keishinkai Medical Corporation.
Actual treatment and clinical response will be conducted at M Regenerative Clinic (Suginami-ku, Tokyo). Furthermore, the culture of Treg cells used in the treatment will be performed under strict quality control at the "Life Science Research Institute," a cell culture and processing facility attached to the aforementioned clinic.
Website Overview
Site Name: Official Website for Treg Therapy for ALS
Launch Date: June 16, 2026 (Tue)
Primary Target Audience: Patients with ALS (Amyotrophic Lateral Sclerosis), their families, and medical professionals
Main Functions: Dissemination of information regarding treatment, acceptance of treatment consultations with staff and online medical examinations by doctors,
publication of explanatory videos on treatment, archive of medical papers as evidence
Corporation and Clinic Overview
【Issuing Corporation】
Corporation Name: Keishinkai Medical Corporation
Location: 11-19-601 Yotsuya Sanei-cho, Shinjuku-ku, Tokyo
Representative: Director Sosuke Iizuka (めしつか そうすけ)
【Treatment Implementation Medical Institution】
Medical Institution Name: M Regenerative Clinic
Location: 5-4-10 Shimotakaido, Suginami-ku, Tokyo
Main Medical Services: Stem cell therapy, cancer immunotherapy, Treg therapy for ALS
【Cell Processing and Research Facility】
Facility Name: Life Science Research Institute
Location: 5-4-10 Shimotakaido, Suginami-ku, Tokyo
Business Activities: Cell culture business (including stem cells), stem cell conditioned medium business, cell banking business
Inquiries Regarding This Matter
Keishinkai Medical Corporation
Phone: 03-5357-8976
Email: [email protected]
※ Please contact the above for inquiries regarding this matter.
FACT BOX
- Source: PR TIMES
- Category: 医療